HLS Financial Statements From 2010 to 2024

HLS Stock  CAD 3.65  0.15  4.29%   
HLS Therapeutics financial statements provide useful quarterly and yearly information to potential HLS Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on HLS Therapeutics financial statements helps investors assess HLS Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting HLS Therapeutics' valuation are summarized below:
Gross Profit
50.8 M
Profit Margin
(0.39)
Market Capitalization
111.3 M
Enterprise Value Revenue
2.2756
Revenue
56.9 M
We have found one hundred twenty available fundamental trends for HLS Therapeutics, which can be analyzed and compared to other ratios and to its competitors. Self-guided Investors are advised to confirm HLS Therapeutics' regular fundamentals against the trend between 2010 and 2024 to make sure the company can sustain itself next year. As of the 12th of December 2024, Enterprise Value is likely to grow to about 199 M, while Market Cap is likely to drop about 70.9 M.

HLS Therapeutics Total Revenue

56.09 Million

Check HLS Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among HLS Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 33.5 M, Interest Expense of 9.2 M or Total Revenue of 56.1 M, as well as many indicators such as Price To Sales Ratio of 1.22, Dividend Yield of 0.0102 or PTB Ratio of 0.82. HLS financial statements analysis is a perfect complement when working with HLS Therapeutics Valuation or Volatility modules.
  
This module can also supplement various HLS Therapeutics Technical models . Check out the analysis of HLS Therapeutics Correlation against competitors.

HLS Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets114 M209.1 M162.4 M
Slightly volatile
Short and Long Term Debt Total51.5 M87.6 M104.6 M
Very volatile
Other Current Liabilities1.6 M1.7 M6.4 M
Very volatile
Total Current Liabilities18 M26.7 M21.1 M
Slightly volatile
Total Stockholder Equity64.7 M97.7 M90.3 M
Slightly volatile
Property Plant And Equipment Net916.8 K965 K2.7 M
Slightly volatile
Accounts Payable8.9 M14.1 M8.5 M
Slightly volatile
Non Current Assets Total173.2 M165 M127.7 M
Slightly volatile
Net Receivables11.6 M10.7 M11.6 M
Very volatile
Common Stock Shares Outstanding23.1 M32.3 M24.1 M
Slightly volatile
Liabilities And Stockholders Equity114 M209.1 M162.4 M
Slightly volatile
Non Current Liabilities Total88.9 M84.7 M54.8 M
Slightly volatile
Inventory10 M9.5 M3.7 M
Slightly volatile
Other Stockholder Equity16.7 M13.9 M11.9 M
Very volatile
Total Liabilities116.9 M111.4 M76.6 M
Slightly volatile
Property Plant And Equipment Gross2.9 M3.1 M3.3 M
Slightly volatile
Total Current Assets32.9 M44.1 M40.9 M
Slightly volatile
Intangible Assets173.4 M162.3 M249.2 M
Pretty Stable
Cash18.1 M22 M24.5 M
Very volatile
Short Term Investments133 K138.1 K152.3 K
Slightly volatile
Good Will9.4 M10.9 M9.5 M
Slightly volatile
Common Stock Total Equity310.8 M296 M151 M
Slightly volatile
Common Stock169.5 M262.1 M140.4 M
Slightly volatile
Other Liabilities1.2 M1.2 M13.1 M
Slightly volatile
Long Term Debt86.2 M82 M124.7 M
Slightly volatile
Capital Surpluse10.3 M15.9 M6.9 M
Slightly volatile
Property Plant Equipment928.3 K1.3 M658.7 K
Slightly volatile
Non Current Liabilities Other1.7 M1.8 M2.9 M
Pretty Stable
Cash And Equivalents20.9 M18.7 M25.4 M
Pretty Stable
Net Invested Capital203.5 M184.4 M280.3 M
Slightly volatile
Short and Long Term Debt9.2 M4.7 M6.6 M
Slightly volatile
Capital Stock276.8 M262.1 M231.3 M
Slightly volatile
Capital Lease Obligations863.5 K884 K959.2 K
Slightly volatile

HLS Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense9.2 M8.7 M5.9 M
Slightly volatile
Total Revenue56.1 M63.1 M64.6 M
Slightly volatile
Gross Profit58.2 M55.5 M36.4 M
Slightly volatile
Other Operating Expenses51 M73.4 M56.1 M
Very volatile
Total Operating Expenses69.1 M65.8 M33.9 M
Slightly volatile
Selling General Administrative10 M8.4 M9.1 M
Slightly volatile
Selling And Marketing Expenses10.4 M19.9 M7.2 M
Slightly volatile
Interest Income207.1 K350 K237.2 K
Very volatile
Reconciled Depreciation35.7 M31.9 M32.5 M
Slightly volatile

HLS Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation33.5 M31.9 M21.2 M
Slightly volatile
Dividends Paid3.9 M2.4 M4.2 M
Slightly volatile
Capital Expenditures179.6 K189 K4.9 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.221.96422.7592
Slightly volatile
Dividend Yield0.01020.01940.0075
Slightly volatile
PTB Ratio0.821.26811.461
Slightly volatile
Days Sales Outstanding42.7461.884659.8038
Pretty Stable
Book Value Per Share1.953.02813.3395
Slightly volatile
Average Payables7.1 M7.5 M6.7 M
Pretty Stable
Capex To Depreciation0.00550.00580.8916
Slightly volatile
PB Ratio0.821.26811.461
Slightly volatile
Sales General And Administrative To Revenue0.180.1330.1824
Slightly volatile
Average Inventory296.4 K312 K376.4 K
Slightly volatile
Capex To Revenue0.00280.0030.0828
Pretty Stable
Cash Per Share0.580.65451.0145
Pretty Stable
Intangibles To Total Assets1.430.77655.2468
Slightly volatile
Current Ratio1.571.65229.5705
Pretty Stable
Receivables Turnover5.65.898121.0973
Very volatile
Graham Number8.017.62496.2938
Slightly volatile
Shareholders Equity Per Share1.953.02813.3395
Slightly volatile
Debt To Equity0.730.88782.4591
Slightly volatile
Capex Per Share0.00560.00590.191
Very volatile
Average Receivables7.3 M11.7 M11.8 M
Very volatile
Revenue Per Share1.861.9553.0773
Slightly volatile
Interest Debt Per Share1.542.95963.6265
Pretty Stable
Debt To Assets0.560.41492.2323
Slightly volatile
Short Term Coverage Ratios3.23.36517.7994
Slightly volatile
Price Book Value Ratio0.821.26811.461
Slightly volatile
Company Equity Multiplier1.872.13991.6555
Slightly volatile
Long Term Debt To Capitalization0.250.45650.5414
Slightly volatile
Total Debt To Capitalization0.260.47030.5144
Pretty Stable
Debt Equity Ratio0.730.88782.4591
Slightly volatile
Quick Ratio1.231.2959.2327
Pretty Stable
Net Income Per E B T1.360.99021.7067
Slightly volatile
Cash Ratio0.780.82258.5388
Pretty Stable
Days Of Sales Outstanding42.7461.884659.8038
Pretty Stable
Price To Book Ratio0.821.26811.461
Slightly volatile
Fixed Asset Turnover68.6365.361770.8813
Pretty Stable
Debt Ratio0.560.41492.2323
Slightly volatile
Price Sales Ratio1.221.96422.7592
Slightly volatile
Asset Turnover0.290.30170.9755
Slightly volatile
Gross Profit Margin0.920.87910.6975
Slightly volatile
Price Fair Value0.821.26811.461
Slightly volatile

HLS Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap70.9 M123.9 M159.6 M
Slightly volatile

HLS Fundamental Market Drivers

Forward Price Earnings185.1852
Cash And Short Term Investments22 M

About HLS Therapeutics Financial Statements

HLS Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how HLS Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue6.6 M6.9 M
Total Revenue63.1 M56.1 M
Cost Of Revenue7.6 M7.2 M
Stock Based Compensation To Revenue(0.01)(0.01)
Sales General And Administrative To Revenue 0.13  0.18 
Revenue Per Share 1.95  1.86 
Ebit Per Revenue(0.16)(0.16)

Pair Trading with HLS Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if HLS Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in HLS Therapeutics will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to HLS Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace HLS Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back HLS Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling HLS Therapeutics to buy it.
The correlation of HLS Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as HLS Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if HLS Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for HLS Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in HLS Stock

HLS Therapeutics financial ratios help investors to determine whether HLS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLS with respect to the benefits of owning HLS Therapeutics security.